FDA approves Papzimeos (zopapogene imadenovec) for the treatment of adults with recurrent respiratory papillomatosis – Precigen
Precigen, Inc. announced that the FDA has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). Papzimeosis the first and only FDA-approved therapy… read more.
